| Domoto-Reilly, Kimiko |
NCT03260920: Intranasal Oxytocin for Frontotemporal Dementia |
|
|
| Active, not recruiting | 2 | 112 | Canada, US | Syntocinon, Intranasal Oxytocin | Lawson Health Research Institute, Weston Brain Institute, Canadian Institutes of Health Research (CIHR), Berry Consultants | Frontotemporal Dementia | 06/23 | 12/24 | | |
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies |
|
|
| Completed | 2 | 130 | US | CT1812 | Cognition Therapeutics, National Institute on Aging (NIA) | Dementia with Lewy Bodies | 11/24 | 11/24 | | |
NCT04363684: ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) |
|
|
| Recruiting | N/A | 2100 | Canada, US | | Mayo Clinic, University of California, San Francisco, National Institute on Aging (NIA), National Institute of Neurological Disorders and Stroke (NINDS) | Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy | 06/25 | 06/25 | | |
| Holden, Samantha |
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies |
|
|
| Completed | 2 | 130 | US | CT1812 | Cognition Therapeutics, National Institute on Aging (NIA) | Dementia with Lewy Bodies | 11/24 | 11/24 | | |
| Active, not recruiting | 2 | 160 | Europe, US | Neflamapimod, VX-745, Placebo | EIP Pharma Inc, National Institute on Aging (NIA), Worldwide Clinical Trials, CervoMed, Inc | Dementia With Lewy Bodies | 08/24 | 03/25 | | |
| Henriquez, Adolfo M |
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies |
|
|
| Completed | 2 | 130 | US | CT1812 | Cognition Therapeutics, National Institute on Aging (NIA) | Dementia with Lewy Bodies | 11/24 | 11/24 | | |
LUCINDA, NCT03649724: The Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's |
|
|
| Recruiting | 2 | 180 | US | Placebo, Eligard 22.5Mg Suspension for Injection | Weill Medical College of Cornell University, National Institute on Aging (NIA), Tolmar Pharmaceuticals | Alzheimer Disease, Mild Cognitive Impairment | 12/25 | 02/26 | | |
| Roberts, Franklin |
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies |
|
|
| Completed | 2 | 130 | US | CT1812 | Cognition Therapeutics, National Institute on Aging (NIA) | Dementia with Lewy Bodies | 11/24 | 11/24 | | |
| Islam, Aasiya |
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies |
|
|
| Completed | 2 | 130 | US | CT1812 | Cognition Therapeutics, National Institute on Aging (NIA) | Dementia with Lewy Bodies | 11/24 | 11/24 | | |
| Tolea, Magdalena |
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies |
|
|
| Completed | 2 | 130 | US | CT1812 | Cognition Therapeutics, National Institute on Aging (NIA) | Dementia with Lewy Bodies | 11/24 | 11/24 | | |
| Active, not recruiting | 2 | 160 | Europe, US | Neflamapimod, VX-745, Placebo | EIP Pharma Inc, National Institute on Aging (NIA), Worldwide Clinical Trials, CervoMed, Inc | Dementia With Lewy Bodies | 08/24 | 03/25 | | |
| Completed | N/A | 336 | US | Provider Educational Intervention | Florida Atlantic University, University of Miami, Palm Beach State College | Alzheimer' Disease | 09/23 | 09/23 | | |
NCT05479552: A Diagnostic Test for Dementia With Lewy Bodies |
|
|
| Active, not recruiting | N/A | 80 | US | Syn-One Test | CND Life Sciences, National Institute on Aging (NIA) | MCI-AD, Early Stage Alzheimer's Disease, MCI-DLB, Early Stage Dementia With Lewy Bodies | 09/25 | 10/25 | | |
